A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

NCT06707610 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Advanced Solid Tumor

Interventions

DRUG: ALK202

Sponsor

Shanghai Allink Biotherapeutics Co., Ltd.